Comparison of 28-days mortality rate in patients with cardiogenic shock receiving between norepinephrine and dopamine.

Faculty of Pharmaceutical Sciences, Chulalongkorn University0 个研究点目标入组 476 人开始时间: 2021年7月6日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients with cardiogenic shock who admitted to the CCU and ICCU at King Chulalongkorn Memorial Hospital between 1 January 2014 to 31 December 2021.
•All adults patients age greater than 18 who receieved norepinephrine or dopamine. Patients diagnosed with cardiogenic shock were identified by the presence of International Classification of Disease, tenth revision, ICD 10th code R570 in the list of diagnosed generated during the course of their hospital stay or identified by clinical criteria (SBP< 90 mmHg despite adequate amount of fluids had been administration and if there were signs of tissue hypoperfusion (e.g. altered mental state, cold extremities, urine output of < 0.5 ml/kg/h or < 30 ml/h, arterial blood pH < 7.35, arterial blood lactate > 2 mmol/L or serum creatinine rising at least 0.3 mg/dL or increasing more than 1.5 to 1.9 times of baseline serum creatinine) or hemodynamic criteria (e.g. cardiac index less than 2.2 L/min/m2 and pulmonary capillary wedge pressure more than 15 mmHg) in 24 to 48 hours before received norepinephrine or dopamine.

•1. Shock from other cause such as hypovolemic shock, sepsis shock or anaphalaxis shock in 24 to 48 hours before received norepinephrine or dopamine.
•2. Patients with cardiogenic shock who recieved both norepinephrine and dopamine.

发起方

Faculty of Pharmaceutical Sciences, Chulalongkorn University